October 4, 2026 · Science & Research Daily Digest
Science, space, biomedicine, and climate research compiled for October 4, 2026, with summaries, links, and brief commentary.
I. Space and Deep Space
1. ESA starts two feasibility studies for a European-led space station (Space)
Summary:
NASASpaceFlight.com reported on October 3 that the European Space Agency has begun studying a European-led space station in parallel with partnerships on commercial stations. The report says two consortia, led by Airbus Defence and Space and by OHB, are running the studies. They started in June and last about nine months, drawing on Europe's contributions to the International Space Station and on the European Service Module supplied for NASA's Orion spacecraft. The work follows member states' endorsement of "A Call to Boost European Space Exploration," which asks ESA to strengthen human and robotic exploration of low-Earth orbit, the Moon, and Mars, and names a European crew-transport capability as a necessary step. The same report notes that Isar Aerospace's Spectrum reached orbit on its second flight on September 5 under the European Launcher Challenge. The station studies are not an approved flight vehicle.
Links:
Commentary:
These are feasibility studies of about nine months, not a funded European station and not a crew-vehicle flight schedule.
II. Biomedicine
2. A trivalent peramivir–Fc conjugate beats baloxavir and CD388 in four influenza mouse models (Antivirals)
Summary:
Nature Communications on October 4 published an open-access paper from the Academy of Military Medical Sciences, the National Engineering Research Center for the Emergency Drug, Tsinghua University, Xiamen University, and the University of Hong Kong. Long-acting drug–Fc conjugate CD388 is already a class of antivirals against influenza A and B, but how Fc conjugation changes the small molecule was undefined. The team built a programmable multivalent antiviral-conjugate platform by click chemistry. Using zanamivir, mono-, di-, and trivalent conjugates with Fc showed higher activity for the trivalent form, AVC-Z3, which aggregates virions and couples entry blockade with restricted release. Trivalent peramivir–Fc, AVC-P3, was stronger than AVC-Z3 in vitro and had a longer in vivo half-life than AVC-Z3 and than CD388 carrying the YTE mutation. In mice infected with H1N1, H3N2, H5N1, or influenza B, AVC-P3 outperformed the other conjugates, baloxavir, and CD388. Funding included China's Innovative Drug Research and Development National Science and Technology Major Project and the National Natural Science Foundation of China.
Links:
Commentary:
Valency changes the mechanism from neuraminidase inhibition to physical cross-linking of virions; outperforming comparators in mice is not a human dose or an approval.
3. Rina-S posts a 45.9% confirmed response rate in 109 people with platinum-resistant ovarian cancer (Oncology)
Summary:
Genmab of Denmark said on October 3, in a late-breaking oral session at the International Gynecologic Cancer Society congress in Montreal, that investigational folate-receptor-alpha antibody-drug conjugate rinatabart sesutecan (Rina-S), which carries a topoisomerase I inhibitor, produced a confirmed objective response in 45.9% of 109 treated patients in Part C of Phase 1/2 RAINFOL-01 (95% confidence interval 36.3–55.7), including five complete responses. Patients had platinum-resistant high-grade serous ovarian, primary peritoneal, or fallopian-tube cancer and received 120 mg/m² every three weeks as monotherapy. More than half (53%) had received three or four prior lines; all had received bevacizumab and a taxane, 49.5% a PARP inhibitor, and 33% mirvetuximab. Median duration of response was 12.1 months, and 51% of responders were still responding at one year. Median progression-free survival was 9.5 months (95% confidence interval 7.6–11.3). Activity did not depend on folate-receptor-alpha level or on prior mirvetuximab. The most common treatment-emergent adverse events included nausea in 67.9%, fatigue in 57.8%, anemia in 57.8%, and neutropenia in 57.8%. Serious adverse events occurred in about one-third of participants, and 5.5% stopped for adverse events. The cohort had no control arm. The drug is not approved, and Phase 3 trials including RAINFOL-02 are still underway.
Links:
Commentary:
The 45.9% figure is a confirmed response rate from a single-arm cohort with more than a year of median follow-up, not a superiority result against standard care, and a congress presentation is not a label.
4. A B-cell senescence signature is enriched in COPD lungs from six people per group (Respiratory)
Summary:
Communications Medicine on October 4 published an open-access paper by Irfan Rahman and colleagues at the University of Rochester Medical Center. Single-cell RNA sequencing of 121,885 lung cells from people with chronic obstructive pulmonary disease and healthy controls, six per group, including donors with and without a smoking history, found significant enrichment (p < 0.05) of senescence-associated gene signatures in B-cell clusters. The transcriptional profile included impaired B-cell differentiation and maturation, higher inflammatory signaling, and dysregulated lipid metabolism, with factors that affect extracellular matrix and cell–cell interactions. Spatial transcriptomics and proteomics supported the single-cell findings. In senescent regions of donor lungs, ligand–receptor interactions between B lymphocytes and alveolar type II cells shifted toward ADGRE5–CD55. The work was supported by the U.S. National Institutes of Health and related grants.
Links:
Commentary:
Six donors per group make B-cell senescence a described feature of the lung microenvironment; they do not show that removing those cells changes lung function.
5. Seven membrane-associated small proteins connect c-di-GMP to sporulation control in C. difficile (Microbiology)
Summary:
Nature Communications on October 4 published an open-access paper by Johann Peltier, Olga Soutourina, and colleagues at the Institute for Integrative Biology of the Cell, Université Paris-Saclay, with Université Paris Cité, Hannover Medical School, and the University of Costa Rica. Elevated cyclic diguanosine monophosphate inhibits sporulation in Clostridioides difficile, and the mechanism had been unclear. The team identified a conserved family of small membrane-associated proteins encoded by genes regulated by a c-di-GMP riboswitch. Transcriptomics showed that c-di-GMP represses these genes, and reporter assays showed riboswitch control by premature transcription termination. Overexpression of one gene, CD1980.2, was enough to turn on sporulation genes, including sigma factors and their regulons, and to increase spore formation. Sporulation efficiency fell as more of the small-protein genes were deleted, and the strain lacking all seven had a severe sporulation defect. Raising c-di-GMP in that deletion mutant did not reduce sporulation further, which supports a model in which the signal blocks spores by repressing this protein family. Funding included the French National Research Agency.
Links:
Commentary:
The pathway explains how the signal shuts off sporulation in laboratory strains; it is not a drug shown to cut C. difficile transmission on a ward.
III. Basic Research
6. Two Asgard archaea crawl on glass at a few micrometers per minute using protrusions (Evolutionary cell biology)
Summary:
Nature on September 30 published an open-access paper by Philipp Radler, Christa Schleper, and colleagues at the University of Vienna, with the Helmholtz Centre for Infection Research, the Institute of Science and Technology Austria, and the Japan Agency for Marine-Earth Science and Technology. The Helmholtz centre issued a companion release on October 2. Anaerobic live-cell microscopy showed that Ca. Lokiarchaeum ossiferum (Lokiarchaea) and Ca. Margulisarchaeum peptidophilum (Hodarchaea) change shape sharply on a minute timescale. Protrusions grew at 1.5 ± 0.6 and 4.8 ± 1.4 micrometers per minute, respectively, and after sticking to glass the cells crawled using those protrusions. Median cell-body speed for L. ossiferum was 1.57 ± 0.93 micrometers per minute. Selected actin inhibitors arrested the dynamics. Swinholide A at 50 ng/ml already blocked new protrusions and abolished migration, which the authors read as evidence for a central role of the Lokiactin cytoskeleton. They argue that this plasticity, unusual among prokaryotes, may have mattered for the emergence of eukaryotic cells from an Asgard archaeon and an alphaproteobacterium.
Links:
- Nature — Dynamic protrusions mediate crawling motility in Asgard archaea
- Helmholtz Centre for Infection Research — Unexpected dynamics of ancient microbes discovered
Commentary:
Inhibitor experiments tie protrusion motion to actin-like filaments, but there is no genetic knockout, and two cultured lineages do not stand in for all Asgard archaea.
7. Lysosomal stress opens TFEB through TBK1/ULK1 phosphorylation of FNIP1 at serine 296 (Cell biology)
Summary:
Nature on September 30 published a paper from the Telethon Institute of Genetics and Medicine in Pozzuoli, Italy, and collaborators, with Gennaro Napolitano as a lead investigator. Fondazione Telethon posted the findings on EurekAlert the same day. Lysosomal adaptation is coordinated by mTORC1, and the FLCN–FNIP complex decides whether mTORC1 can inhibit TFEB, the master regulator of catabolic programs, but how FLCN:FNIP itself is controlled had been unclear. The new pathway is nutrient-independent: the v-ATPase recruits TBK1 or ULK1 to lysosomes through the adaptor TAX1BP1, TBK1/ULK1 phosphorylates FNIP1 at serine 296, FLCN is inhibited, and TFEB moves into the nucleus. Recurrent ATP6V1B2 v-ATPase mutations found in follicular lymphoma constitutively activate the pathway, hyperactivate TFEB, and support lymphoma proliferation. Napolitano told EurekAlert that because the step sits upstream of TFEB, the kinases are closer to a drug target than the transcription factor, which has been hard to drug directly.
Links:
- Nature — A TBK1/ULK1 signalling axis couples lysosomal stress to TFEB activation
- EurekAlert — Newly discovered pathway unlocks the therapeutic potential of TFEB
Commentary:
Serine 296 connects lysosomal stress to kinases that are already familiar; the therapeutic language in the release does not come with a candidate compound or patient data.
8. Mouse lung tumors evade KRAS inhibitors by amplifying the gene or by becoming squamous and KRAS-independent (Cancer mechanisms)
Summary:
Nature Genetics on September 30 published a paper by Nicolas Mathey-Andrews, Carrie L. Rodriguez, Tyler Jacks, and colleagues at MIT's Koch Institute, and MIT News reported it the same day. In genetically engineered mouse lung adenocarcinomas carrying the mutation targeted by approved KRAS inhibitors, treatment responses were rapid but incomplete, and residual tumors transcriptionally resembled alveolar epithelium. With continued treatment, the team invariably saw Kras amplification. To model oncogene-independent resistance, functional CRISPR approaches promoted squamous lineage change. DeltaNp63 was sufficient to turn alveolar organoids squamous in vitro and to make them insensitive to KRAS inhibition. In vivo, loss of Nkx2-1 and/or ectopic Sox2 poised tumors for squamous commitment; SOX2 alone could not start the transition. Squamous-transformed tumors showed no evidence of KRAS/MAPK reactivation. The work is in mice and organoids, not a new clinical readout.
Links:
- Nature Genetics — Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance
- MIT News — Lung cancers can use two different mechanisms to evade KRAS-inhibiting drugs
Commentary:
Amplification still uses the same target, while squamous transformation turns the dependency off; both routes are from mice, and neither is yet a combination regimen.
IV. Climate and Environment
9. After clouds and temperature, Hong Kong's 338,550 rooftops hold 3.77 terawatt-hours of solar potential a year (Energy)
Summary:
Communications Sustainability on October 3 published an open-access paper by Lai Yiu Tong, Jungho Im, and colleagues. A machine-learning framework that combines high-frequency satellite and ground observations estimates rooftop solar potential at 0.5-meter resolution for 338,550 buildings in Hong Kong over 2016–2024. All-sky surface radiation averages about 50% below clear-sky values. After module temperature is included, citywide technical potential falls from 3.85 to 3.77 terawatt-hours per year, about 4.98% of end-use energy and 8.28% of electricity use. Yuen Long alone accounts for 0.718 terawatt-hours. Lifecycle accounting gives a net reduction of 24.9 billion kilograms of carbon dioxide, with a mean carbon payback of 8.18 years. Under the local feed-in tariff, mean financial payback is 3.49 to 6.42 years, and more than 90% of buildings meet household affordability thresholds. Among 2,695 commercial buildings, 18.9% could potentially cut electricity drawn from the grid by 30% or more with full rooftop coverage and storage. The paper notes that solar is now 0.37% of Hong Kong's local generation mix, and that the estimate assumes roofs can be fully covered.
Links:
Commentary:
The 3.77 terawatt-hours is already about 37% below a 5.98-terawatt-hour estimate that ignored clouds; treating the building footprint as fully usable roof can still overstate what can actually be installed.
Today's Summary
- Space: Two ESA feasibility studies for a European-led station, led by Airbus and OHB, run about nine months in parallel with commercial-station options, and they are not an approved vehicle.
- Biomedicine: Trivalent peramivir–Fc beat baloxavir and CD388 in four influenza mouse models. Rina-S had a 45.9% confirmed response rate in 109 people with platinum-resistant ovarian cancer, in a cohort with no control arm. Seven small proteins connect c-di-GMP to sporulation in C. difficile.
- Basic research: Two Asgard archaea crawl on glass using an actin-like cytoskeleton. TBK1/ULK1 phosphorylation of FNIP1 at serine 296 lets TFEB enter the nucleus. Mouse lung tumors can also escape KRAS dependence by turning squamous.
- Climate: After clouds and temperature, Hong Kong rooftop solar potential is 3.77 terawatt-hours a year, with a lifecycle net cut of 24.9 billion kilograms of carbon dioxide, assuming roofs can be fully covered.
Daily Framing:
Today was a mechanism-and-single-arm day: archaeal crawling, a lysosomal switch, and multivalent flu conjugates all produced experimental readouts that can be checked, while the 45.9% ovarian-cancer response came from a congress cohort with no control arm.
This digest is compiled from real-time search results and is for reference only.